Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.90 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 1.20%. A quarter ago, it was expected that this company would post a loss of $0.69 per share when it actually produced a loss of $0.58, delivering a surprise of 15.94%. Over the last four quarters, the company h ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter ...

Exhibit 99.1 ¦KYMERA Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to dose ranging Phase 2b studies to accelerate overall development timelines; completion of both expanded trials expected by mid-2026 KT-295, a new TYK2 degrader, selected as the deve ...

KT-621, an oral degrader, is the first STAT6 targeted medicine to enter clinical development, with the potential to address multiple immuno-inflammatory diseases KT-621 has demonstrated dupilumab-like activity and was well tolerated in a wide variety of preclinical models of TH2 diseases Phase 1 healthy volunteer data expected to be reported in the first half of 2025 WATERTOWN, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advan ...

WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report third quarter 2024 financial results on October 31, 2024, and will host a conference call at 8:30 a.m. ET. To access the October 31 conference call via phone, please dial +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics ...

Core Insights - Kymera Therapeutics has received FDA clearance for its investigational New Drug application for KT-621, a first-in-class oral STAT6 degrader aimed at treating multiple allergic and atopic diseases [1][3] - The company plans to initiate a phase I study for KT-621 in healthy volunteers later this month, with data expected in the first half of 2025 [2] Company Pipeline Progress - Kymera recently raised $225 million through a public offering to advance its pipeline of degrader programs [5] - The company is also progressing with KT-474, a first-in-class IRAK4 degrader, with plans for pivotal studies following positive preliminary safety and efficacy data [6][7] - Ongoing phase I studies for KT-253 and KT-333 are showing promising antitumor responses, with enrollment expected to complete in the second half of 2024 [9][10] Competitive Landscape - Sanofi and Regeneron's Dupixent, an injectable monoclonal antibody, is an established therapy for allergic and atopic diseases, validating the STAT6 targeting approach [4]

KT-621 has demonstrated dupilumab-like activity and was well tolerated in a wide variety of preclinical models of TH2 diseases KT-621 is expected to start Phase 1 in October, with Phase 1 data in the first half of 2025 WATERTOWN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the clearance of its Investigational New Drug (I ...

KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease KT-621 demonstrated strong degradation of STAT6 in human sensory neurons resulting in inhibition of IL-13- induced itch- and pain-related gene transcripts with the potential to alleviate these symptoms in atopic dermatitis patients KT-621 expected to start Phase 1 in the second half of 2024, with Phase 1 data in the first half of 2025 WATERTOWN, Mass., Sept. 25, 2024 (GL ...

Core Insights - Kymera Therapeutics reported a narrower loss of 58 cents per share in Q2 2024, better than the expected loss of 69 cents, and improved from a loss of 67 cents per share in the same quarter last year [2][15] - The company experienced a significant increase in collaboration revenues, totaling $25.6 million, which exceeded the consensus estimate of $12 million and represented a 55.3% increase year-over-year [2][3] Financial Performance - Research and development expenses rose to $59.2 million, a 29.3% increase year-over-year, driven by investments in the targeted protein degradation platform and increased occupancy costs [4] - General and administrative expenses increased to $17.4 million, up 22.9% year-over-year, primarily due to higher legal and professional service fees [5] - As of June 30, 2024, the company had $702.4 million in cash and equivalents, expected to last into the first half of 2027, providing a financial cushion for ongoing and upcoming clinical trials [6] Pipeline Developments - Sanofi plans to expand mid-stage studies on KT-474 towards pivotal studies, a first-in-class IRAK4 degrader for immune-inflammatory diseases [7][8] - Kymera is set to initiate a phase I study on KT-621 in the second half of 2024, with data expected in the first half of 2025 [9] - Ongoing phase I studies for KT-253 and KT-333 have shown promising results, with KT-253 demonstrating antitumor activity in various tumor types and KT-333 showing responses in hematological malignancies [11][13][14] Market Position and Outlook - Estimates for Kymera Therapeutics have trended downward, with a consensus estimate shift of -11.79% [15] - The company holds a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [17] - In comparison, Denali Therapeutics, a peer in the biomedical industry, has seen a 13.3% gain over the past month, highlighting competitive dynamics within the sector [18]

WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events: Wells Fargo 2024 Healthcare Conference in Boston, MA on September 4 at 3:00 p.m. ET; Morgan Stanley 22nd Annual Global Healthcare Conference in New York, ...